Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck KGaA, Ono Pharmaceutical deal

Merck is returning rights to Ono for ceralifimod ( ONO-4641), a sphingosine 1-phosphate

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE